Año 2022 / Volumen 114 / Número 1
Original
Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

10-15

DOI: 10.17235/reed.2021.7683/2020

Rocío Ferreiro-Iglesias, Manuel Barreiro-de Acosta, Javier López-Díaz, Iria Bastón Rey, Juan Enrique Domínguez-Muñoz,

Resumen
Background: monocytes play an important role in the pathogenesis of inflammatory bowel disease but data are scarce regarding activity biomarkers, above all in patients under biologic therapies. Objective: the aim of this study was to evaluate the value of monocyte measurements in predicting flares in inflammatory bowel disease patients under maintenance treatment with anti-TNF. Methods: a prospective, observational cohort study was designed. Relapse was defined as a Harvey-Bradshaw score > 4 in Crohn’s disease, and a partial Mayo score ≥ 2 in ulcerative colitis. Monocyte concentration was quantified at 4-month intervals for twelve months. A total of 95 consecutive patients were included. Median age was 42 years, 50.5 % were female, and 75 % had Crohn’s disease. Results: sixteen months after inclusion, 65 (68.4 %) patients remained in clinical remission. Mean monocyte count preceding a relapse was 563 (standard deviation: 144) compared to 405 (standard deviation: 177) in patients who remained in remission. Final monocyte count was significantly different between relapse and remission in Crohn’s disease (0.82; 95 % CI: 0.71-0.90; p < 0.005). According to the multivariate analysis, only monocytes and fecal calprotectin were related to more relapses. Conclusion: in conclusion, in inflammatory bowel disease patients under anti-TNF therapy, repeat monocyte counts could help monitor patients, at least in Crohn’s disease.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55(3):426-31. DOI: 10.1136/gut.2005.069476
2. Gisbert JP, González Lama Y, Maté J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 2007;30(3):117-29. DOI: 10.1157/13100073
3. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009;2:221.
4. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.
5. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early stage Crohn’s disease. Gastroenterology 2010;138:463-8.
6. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
7. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-5.
8. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective longitudinal study. Gut 2008;57:1518-23.
9. Oyaert M, Boel A, Jacobs J, et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med 2017;55:1564-73.
10. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2014;2:30-7.
11. Coorevits L, Baert FJ, Vanpoucke HJ. Fecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med 2013;51:825-31.
12. Mee AS, Berney J, Jewell DP. Monocytes in inflammatory bowel disease: absolute monocyte counts. J Clin Pathol 1980;33:917-20.
13. Zhou L, Braat H, Faber KN, et al. Monocytes and their pathophysiological role in Crohn’s disease. Cell Mol Life Sci 2009;66:192-202.
14. Thayer WR Jr, Charland C, Field CE. The subpopulations of circulating white blood cells in inflammatory bowel disease. Gastroenterology 1976;71:379-84.
15. Jakubzick C, Gautier EL, Gibbings SL, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 2013;39:599-610.
16. Cherfane C, Anderson AJ, Ramos Rivers C, et al. Is monocytosis a biomarker of severity in inflammatory bowel disease? Analysis of a 6 year, prospective natural history registry. Gastroenterology 2016;150(4):S42. DOI: 10.1016/S0016-5085(16)30266-9
17. Cherfane C, Gessel L, Dominic C, et al. Monocytosis and a low lymphocyte to monocyte ratio are effective biomarkers of ulcerative colitis disease activity. Inflamm Bowel Dis 2015;21:1769-75.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of gastroenterology. Can J Gastroenterol 2005;19(suppl A):5A-36A. DOI: 10.1155/2005/269076
19. Mee AS, Berney J, Jewell DP. Monocytes in inflammatory bowel disease: absolute monocyte counts. J Clin Pathol 1980;33:917-20.
20. Zhou L, Braat H, Faber KN, et al. Monocytes and their pathophysiological role in Crohn’s disease. Cell Mol Life Sci 2009;66:192-202.
21. La Manna MP, Orlando V, Dieli F, et al. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. Plos One 2017;12(2):e0171358. DOI: 10.1371/journal.pone.0171358
22. Wei XB, Chen F, Huang JL, et al. Novel risk biomarker for infective endocarditis patients with normal ventricular ejection fraction – monocyte to high density lipoprotein colesterol ratio. Cir J 2007;82:283-8.
23. Woollard KJ, Geissman F. Monocytes in aterosclerosis: subsets and functions. Nat Rev Cardiol 2010;7:77-86.
24. Dutta P, Nahrendorf M. Monocytes in myocardial infarction. Arterioscler Thromb Vasc Biol 2015;35:1066-70.
25. Klimek E, Mikolajcyk T, Sulicka J, et al. Blood monocyte subsets and selected cardiovascular risk markers in rheumatoid arthritis of short duration in relation to disease activity. Biomed Res Int 2014;2014:736853.
26. Hensel M, Grädel L, Kutz A, et al. Peripheral monocytosis as a predictive factor for adverse outcome in the emergency department. Medicine 2017;96:e7404. DOI: 10.1097/MD.0000000000007404
27. García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 2010;4(2):144-52. DOI: 10.1016/j.crohns.2009.09.008
28. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflam- matory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8.
29. Lobatón T, López-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis 2013;7:641-51.
30. Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013;19:1034-42.
31. Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo A, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol 2016;50:147-51.
32. Ferreiro Iglesias R, Barreiro de Acosta M, Lorenzo Gonzalez A, et al. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn’s disease patients on maintenance treatment with adalimumab. Scand J Gastroenterol 2016;51:442-7.
33. Ferreiro Iglesias R, Barreiro de Acosta M, Lorenzo A, et al. Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy: a prospective longitudinal cohort study. J Clin Gatroenterol 2018;52:229-34.
34. Valenzuela JE, Pereñiguez Lopez A, Perez Fernandez V, et al. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn’s disease. Rev Esp Enferm Dig 2016;108:394-400. DOI: 10.17235/reed.2016.4318/2016
Artículos relacionados

Carta

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Carta

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Carta

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Carta

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Imagen en Patología Digestiva

Intestinal and perianal tuberculosis: an uncommon clinical presentation and challenging diagnosis

DOI: 10.17235/reed.2022.8988/2022

Imagen en Patología Digestiva

Enfermedad de Crohn cutánea periostomal por contigüidad

DOI: 10.17235/reed.2022.8909/2022

Carta

Neumonitis intersticial por mesalazina en la era COVID

DOI: 10.17235/reed.2022.8635/2021

Carta

Efecto del Adacolumn® en colitis ulcerosa con COVID-19

DOI: 10.17235/reed.2020.7156/2020

Carta

Síndrome de Sweet en el brote grave de colitis ulcerosa

DOI: 10.17235/reed.2020.6995/2020

Carta al Editor

Colitis ulcerosa con afectación gástrica y duodenal

DOI: 10.17235/reed.2017.4685/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Carta al Editor

Adnexal localization of Crohn’s disease and recurrent massive ovary cysts

DOI: 10.17235/reed.2016.4301/2016

Caso Clínico

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Caso Clínico

Enfermedad de Crohn metastásica en pediatría

DOI: 10.17235/reed.2016.3948/2015

Carta al Editor

Debut conjunto de enfermedad de Crohn y síndrome de Sweet

DOI: 10.17235/reed.2015.3842/2015

Caso Clínico

Afectación ovárica en la enfermedad de Crohn: una complicación rara

DOI: 10.17235/reed.2015.3764/2015

Instrucciones para citar
Ferreiro-Iglesias R, Barreiro-de Acosta M, López-Díaz J, Bastón Rey I, Domínguez-Muñoz J. Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study. 7683/2020


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1426 veces.
Este artículo ha sido descargado 132 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 25/11/2020

Aceptado: 14/01/2021

Prepublicado: 25/01/2021

Publicado: 10/01/2022

Tiempo de revisión del artículo: 45 días

Tiempo de prepublicación: 61 días

Tiempo de edición del artículo: 411 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas